JP Morgan Chase
VRPX

JP Morgan Chase’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

JP Morgan Chase’s Portfolio VRPX Stock Details VRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-17
Closed -$1.37K – 8052
2023
Q4 		$1.37K Buy
+17
New +$2.55K ﹤0.01% 6789
2022
Q2 		– Sell
-11
Closed -$6K – 7022
2022
Q1 		$6K Buy
+11
New +$6.41K ﹤0.01% 6301

Other funds holding VRPX

TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SRCM
Signature Resources Capital Management Newport Beach, California $254M AUM 26.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

JP Morgan Chase's VRPX Position: Q1 2024 in Review

JP Morgan Chase sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q1 2024, closing a stake of 17 shares — an estimated $1.37K sold.

JP Morgan Chase first reported a position in VRPX in Q1 2022 and held it in 2 quarters. The position peaked at $6K in Q1 2022. 3 funds tracked by Wall St. Rank hold VRPX as of Q1 2024.

  • JP Morgan Chase reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • JP Morgan Chase sold 17 Virpax Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $1.37K.
  • JP Morgan Chase first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • JP Morgan Chase's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $6K in Q1 2022.
  • 3 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.